Literature DB >> 7107378

Enhancement of chemotherapy agents.

N J McNally.   

Abstract

The interaction in vivo between misonidazole and cytotoxic drugs is reviewed. In general MISO interacts best with bifunctional alkylating agents and nitrosoureas when there is generally a therapeutic gain at large MISO doses. The interaction is unlikely to be a result of pharmacokinetic effects of MISO, but may reflect its ability to inhibit recovery from drug induced damage. It is important to extend these studies to clinically relevant MISO doses simulating human pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7107378     DOI: 10.1016/0360-3016(82)90691-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  33 in total

Review 1.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

2.  Misonidazole and CCNU chemotherapy for recurrent primary brain tumor.

Authors:  D S Fulton; R C Urtasun; S McKinnon; H Tanasichuk
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

3.  Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.

Authors:  P E Noker; L Simpson-Herren; S D Wagoner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo.

Authors:  B A Teicher; T S Herman; S A Holden; K N Cathcart
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 5.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

6.  Enhancement of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) toxicity by acetohydroxamic acid analogues of 3-nitropyrazole in vitro.

Authors:  R T Mulcahy; D J Wustrow; R R Hark; A S Kende
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

7.  Potentiation of CCNU activity by misonidazole in metastases.

Authors:  D W Siemann; K L Alliet
Journal:  Clin Exp Metastasis       Date:  1987 Jan-Mar       Impact factor: 5.150

8.  Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.

Authors:  F Y Lee; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 9.  Immunotoxin therapy for CNS tumor.

Authors:  Edward Rustamzadeh; Walter C Low; Daniel A Vallera; Walter A Hall
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

10.  Cytotoxicity of antitumor platinum complexes with L-buthionine-(R,S)-sulfoximine and/or etanidazole in human carcinoma cell lines sensitive and resistant to cisplatin.

Authors:  S E Brooks; T T Korbut; N P Dupuis; S A Holden; B A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.